文献速递肥胖与代谢综合征糖尿病

观点对决:手术治疗与药物治疗在肥胖管理中的选择

Point-Counterpoint Debate: Surgery vs Medical Treatment for the Management of Obesity.
PubMed 文献 · J Clin Endocrinol Metab · 2025-01-01

本文总结2024年6月内分泌学会会议上Schauer与Rothberg两位医生关于肥胖最佳管理策略的辩论,探讨代谢手术与高强度医学管理(含生活方式干预和药物治疗)在机制、结局、安全性、生活质量和成本效益方面的差异。两种干预均带来显著健康获益,选择应基于患者个体需求、健康状况、目标减重和个人偏好。

要点

  • 代谢手术带来显著且持续的减重、2型糖尿病等合并症改善及死亡率降低,且具成本效益。
  • 高强度医学管理可带来有意义的体重下降和健康改善,但需患者依从并面临药物副作用和费用挑战。
  • 选择应基于个体需求、健康状况、目标减重和个人偏好,多学科个性化管理可能带来最佳结局。

核心结论

  • 代谢手术与高强度医学管理均带来显著健康获益;选择应基于患者个体需求、健康状况、目标减重和个人偏好。
  • 代谢手术可能更适合严重肥胖或合并症控制不佳者,医学管理可能更适合肥胖程度较轻且倾向非手术方案者。
  • 未来研究应探讨手术与医学管理的联合效果,并提高这些治疗的可及性和可负担性。
  • 多学科个性化管理可能为这一复杂健康问题带来最佳结局。

研究设计与样本

  • 本文为2024年6月内分泌学会会议上Schauer与Rothberg两位医生关于肥胖最佳管理策略的辩论总结。

主要发现

  • 代谢手术带来显著且持续的减重、2型糖尿病等合并症改善及死亡率降低,且具成本效益。
  • 代谢手术存在手术相关风险和长期并发症,且前期费用高限制其可扩展性。
  • 高强度医学管理包括综合生活方式干预和药物治疗,带来有意义的体重下降和健康改善,但有时不如手术显著。
  • 高强度医学管理优先考虑行为改变且具成本效益,但需患者依从并面临药物副作用和费用挑战。

临床怎么用

  • 选择代谢手术或高强度医学管理应基于患者个体需求、健康状况、目标减重和个人偏好。
  • 代谢手术可能更适合严重肥胖或合并症控制不佳的个体,医学管理可能更适合肥胖程度较轻且倾向非手术方案者。
  • 多学科个性化管理可能为肥胖这一复杂健康问题带来最佳结局。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Obesity is a chronic, relapsing condition with severe health risks and a huge economic burden. Effective interventions for severe obesity include bariatric or metabolic surgery and high-intensity medical management involving lifestyle changes and pharmacotherapy. This article summarizes the debate between Drs. Schauer and Rothberg at the June 2024 Endocrine Society meeting regarding the optimal approach to managing obesity, exploring mechanisms, outcomes, safety, quality-of-life, and cost-effectiveness. Metabolic surgery results in substantial and sustained weight loss, improvements in comorbidities such as type 2 diabetes, and reduced mortality, and it is cost-effective. However, it carries risks associated with surgery and long-term complications, and its high upfront costs limit its scalability. Conversely, high-intensity medical management, which includes comprehensive lifestyle interventions and pharmacotherapy, leads to meaningful, though sometimes less substantial, weight loss and health improvements. The latter approach prioritizes behavioral changes and is cost-effective but requires patient adherence and faces challenges with medication side effects and costs. Both interventions offer substantial health benefits; the choice between them should consider individual patient needs, health status, target weight loss, and personal preferences. Metabolic surgery may be more suitable for individuals with severe obesity or when comorbidities are inadequately controlled, whereas medical management may be more suited to patients with less severe obesity and those preferring nonsurgical options. Future research should investigate the combined effects of surgery and medical management and enhance access to and affordability of these treatments. A multidisciplinary, personalized approach will likely yield the best outcomes in managing this complex health issue.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Schauer PR, Rothberg AE. Point-Counterpoint Debate: Surgery vs Medical Treatment for the Management of Obesity. J Clin Endocrinol Metab. 2025. PMID: 39693237. doi:10.1210/clinem/dgae888

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。